7:30 am Check In, Morning Coffee & Light Refreshments
8:20 am Chair’s Opening Remarks
Evaluating Novel ADC Formats & Payloads in the Clinic – How Do They Perform Against Classical ADCs?
8:30 am Investigating the Clinical Performance of Zelenectide Pevedotin & BT5528 to Understand Class Effect Differences of Bicycle Toxin Conjugates Against Classical ADC Formats
Synopsis
• Laying out the emerging safety profiles of zelenectide pevedotin and BT5528, and comparing toxicity characterisation against classical ADC formats
• Delving into BT5528 clinical toxicity profile against EphA2 in contrast to ADCs against the same target
• Rationalising preclinical and clinical differences with PKPD analysis and understanding the advantages of BTCs design and performance
9:00 am Versatile & Robust Chemical Site-Specific Conjugation Platform: AJICAP® Technology
Synopsis
• AJICAP® Conjugation: Examining how site-specific technologies are being employed in many of the next-generation ADCs due to the enhancement of clinically relevant biological properties observed in various preclinical studies
• AJICAP® Linker: Demonstrating a novel hydrophilic linker technology that enables the versatile synthesis of homogenous DAR = 1, 2, 4, 8, and higher
• Showcasing bispecific and trispecific antibodies produced by a fully chemical conjugation technology
9:30 am Detailing Clinical Development of OncoFAP: a Small Molecule Conjugate Targeting Fibroblast Activation Protein in Solid Tumours
Synopsis
• Exploring ongoing OncoFAP tumour target activity in first-in-human imaging studies in solid tumours
• Assessing OncoFAP anti-tumour response as a monotherapy and in combination with immunotherapies
• Contrasting anti-cancer properties of small-molecule conjugates against antibody-drug conjugates
10:00 am Morning Break & Networking
Discovery
Chair: Lenka Sadilkova, Director, Non-Clinical Projects, Mablink
Bioscience, an Eli Lilly Subsidiary
Download the Full Event Guide for full details
Showcasing Challenges & Opportunities in Novel Conjugate Design & Development
11.00 am Bispecific & Biparatopic Antibody Drug Conjugates: Evaluating Strategies & Challenges
• Exploring BpAbs and BpADCs MoA beyond classical antibodies
such as enhanced avidity binding, locking receptor conformation, faster internalisation and payload delivery to low cancer cell populations
• Engaging multiple antigens and cells simultaneously by bispecific ADCs to elicit synergistic effects such as killing a broader spectrum of tumour cells and promoting payload uptake
• Discussing BpADCs and BsADCs design and formats, target and linkerpayload selections, clinical status and limitations
Alain Beck, Senior Director, Biologics CMC Developability, Pierre Fabre
11.30 am Showcasing Enhanced Tumour Penetration & Activity of Antibody Fragment Conjugates Using Novel Site-Specific Conjugation
• Introducing novel site-specific conjugation technology allowing one-step conjugation and simplification of in-process testing
• Applying one-step conjugation to antibody variable region to develop fragment-drug conjugates
• Assessing increased tumour penetration and activity properties of fragment conjugates against HER2 and EGFR/cMET
NingNing Ma, Professor, Shenyang Pharmaceutical University
12.00 pm Roundtable Session: ADCs vs Novel Conjugates – What are the Pros & Cons of Novel Payload & Targeting Moiety Development?
• What progress has been made and what is yet to be demonstrated across DACs, ISACs, and other non-cytotoxic payloads?
• Debating the advantages and disadvantages of novel targeting moiety conjugate development
• What are the bottlenecks preventing novel conjugates matching classical ADCs?
12.30 pm Lunch & Learn Sessions Presented by
Innovating Linker Chemistry to Widen Applications & Maximise Tumour Payload Delivery
1.30 pm Leveraging Glycan Linker Chemistry & Site-Specific Conjugation to Improve ADC Performance
• Understanding the current limitations of linker chemistry on ADC properties
• Considering the biophysical characterisation of ADCs with different linker design and conjugation site
• Discussing how glycan site-specific conjugation can improve the performance of ADCs
David Huang, Head, Medicinal Chemistry, OBI Pharma
2.00 pm Linker-Payload Design & ADC Human MTD: Progressing from Chemistry to the Clinic
• Evaluating T-moiety linkers for hydrophobic payloads e.g. exatecan to overcome resistance and expand the therapeutic window of ADCs
• Explaining implications of liker chemistry in preclinical in vivo efficacy and safety
• Contextualising impact on human MTD from ongoing clinical studies
Xiaona Jing, Senior Vice President, Global Product Development & Partnering, Multitude Therapeutics
3:00 pm Afternoon Break & Networking
Leveraging Biomarkers & Diagnostic Tools to Inform Patient Selection Strategies for Precision Medicine ADC Development
3:30 pm Targeted Cancer Therapy for Patients With 17p Deletion
Synopsis
• Breaking down clinical profile and new phase II escalation data of HDP-101 targeting BCMA in myeloma patients
• Laying out retrospective analysis and investigation in deletion models of 17p deletion as a biomarker and patient selection tool for amanitin payload ADCs
• Discussing future directions for clinical development and potential for patient selection investigation for precision medicine ADC development
4:00 pm Panel Discussion: Evaluating the Need for Biomarker & Patient Selection Tools in an Increasingly Busy ADC Field: What are the Predictions for Future ADC Precision Medicine Approaches?
Synopsis
• What is the current need and appetite for ADC biomarker development and patient selection strategies heading into 2025?
• Discussing the different methodologies across machine learning and digital pathology to quantify IHC derived ADC target expression
• Addressing the challenges and opportunities of biomarker analysis to select patient populations to benefit from specific ADCs
• Summarising future predictions for precision medicine ADC development